Wassim Abida, MD, PhD

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the frequency of mutations for patients with prostate cancer.

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Wassim Abida, MD, PhD, assistant member and assistant attending physician in the Genitourinary Oncology Program at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with prostate cancer.